Chinese Academy of Medical Sciences: Lymphoma trials

The registry lists 11 Lymphoma studies with Chinese Academy of Medical Sciences as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Low-dose Radiotherapy in iNHLStatus unknownNCT05543070Phase 2
• Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownNCT05149170Phase 2
• Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell LymphomaStatus unknownNCT04511351Not applicable
• Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell LymphomaStatus unknownNCT04425824Phase 2
• Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Status unknownNCT04023916Phase 2
• GR1405 Injection in Patients With Advanced Solid Tumor or LymphomaStatus unknownNCT03731390Phase 1
• Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell LymphomaStatus unknownNCT03630731Phase 2
• Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaStatus unknownNCT03410004Phase 2
• Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeStatus unknownNCT02560441Phase 2
• GDP in Frontline Chemotherapy for Patients With PTCL-NOSStatus unknownNCT02404571Phase 2
• Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell LymphomaCompletedNCT02276248Phase 2